1 Staphylococcal superantigens promote bacterial persistence following

2 postoperative surgical site infection

- 3
- 4 Karine Dufresne^{1*}, Stephen W. Tuffs^{1,2*}, Nicholas R. Walton¹, Katherine J. Kasper¹, Ivor
- 5 Mohorovic¹, Farah Hasan¹, Tracey Bentall³, David E. Heinrichs¹, Johan Delport⁴, Tina S.
- 6 Mele^{3,5}, and John K. McCormick¹
- 7
- 8 ¹ Department of Microbiology and Immunology, University of Western Ontario, London,
- 9 Canada
- 10 ² Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
- ³ Division of Critical Care Medicine, Department of Medicine, University of Western
- 12 Ontario, London, Canada
- 13 ⁴ Department of Pathology, University of Western Ontario, London, Canada
- ⁵ Division of General Surgery, Department of Surgery, London Health Sciences Centre,
- 15 University Hospital, London, Canada
- 16
- ^{*}KD and SWT contributed equally to this work.
- 18
- 19 Correspondence: John K McCormick, Department of Microbiology and Immunology,
- 20 University of Western Ontario, London, Ontario, Canada (john.mccormick@uwo.ca).

21 Abstract

22 Staphylococcus aureus is a predominant cause of postoperative surgical site infections and 23 persistent bacteremia. Here we describe a patient that following a total knee arthroplasty subsequently experienced three episodes of S. aureus bacteremia over a period of 4 24 months. The initial blood stream isolate (SAB-0429) was a clonal complex (CC) 5 and 25 26 methicillin resistant S. aureus (MRSA), whereas two subsequent blood stream isolates 27 (SAB-0485 and SAB-0495) were CC5 isolates but methicillin sensitive S. aureus (MSSA). 28 The two latter isolates harbored a plasmid encoding three superantigen genes not present 29 in the primary MRSA isolate. SAB-0485 and SAB-0495 expressed the plasmid encoded staphylococcal enterotoxin R (SER) exotoxin and demonstrated increased superantigen 30 31 activity compared with SAB-0429. Compared to SAB-0429, the latter isolates also 32 demonstrated an increased bacterial burden in a mouse bacteremia model that was 33 dependent on increased IFN_y production. Curing of the plasmid from SAB-0485 reduced 34 this virulence phenotype. These findings suggest that the superantigen exotoxins may 35 provide a selective advantage in chronic postsurgical infections.

36

37 Keywords. *Staphylococcus aureus*, superantigen, surgical site infection, bacteremia.

38 Introduction

39 Staphylococcus aureus is a common human colonizer and opportunistic pathogen capable 40 of causing a wide array of infections that can range from superficial skin lesions to invasive 41 infections including endocarditis, osteomyelitis and bacteremia. Fatality rates for S. aureus 42 bacteremia (SAB) in both community and hospital settings are approximately 20-30% [1,2] 43 and methicillin-resistant S. aureus (MRSA) strains are of major concern as treatment with antibiotics often fail to clear the bacteria within the patients until a correct regimen is 44 found [3]. S. aureus is also an important cause of post-surgical site infections (SSIs) where 45 46 infection due to MRSA has been related to a 7-fold increased risk of death, a 35-fold 47 increased risk of hospital re-admission, and over three weeks of additional hospitalization [4]. When compared to matched control cases, orthopedic SSIs prolong hospital stays for 48 49 an average of 2 weeks, approximately doubling the rates of re-hospitalization, increasing 50 hospital costs by ~300% [5,6]. Orthopedic SSI can also result in a decreased quality of life 51 due to increased physical limitations from the infection [5]. For these reasons, S. aureus 52 decolonization strategies of the orthopedic surgical team and of patients have been 53 implemented and demonstrate a reduction of the total number of surgical site infections 54 [7-9].

55 Both MRSA and methicillin-sensitive S. aureus (MSSA) can survive and persist 56 during infection by manipulating the host using multiple virulence factors [10], including 57 a unique family of toxins called superantigens (SAgs) [11]. SAgs trigger large scale activation of T cells independent of antigen presentation and this aberrant activation can 58 59 lead to an overwhelming cytokine storm disease known as toxic shock syndrome [12]. 60 During experimental bloodstream infection, S. aureus can survive and proliferate in 61 organs including the liver and kidney and, in this context, staphylococcal SAgs can 62 dramatically enhance bacterial burden in the liver through the production of pathogenic levels of IFNy that impede macrophage activity [13]. Conversely, the role of 63 staphylococcal SAgs during mucosal colonization is less well understood but these toxins 64 65 may function as immunological checkpoints in the nares, a major site of S. aureus 66 colonization [14].

67 In this study, we characterized three consecutive clonal complex 5 (CC5) isolates 68 of *S. aureus* acquired from the same patient after recurrence of an orthopedic SSI. Strains 69 were isolated at days 19, 107 and 128 from the original surgical procedure, and the two 70 latter strains differed from the primary isolate by the presence of a SAg-encoding plasmid. 71 Following extensive genetic and phenotypic characterization of these isolates, including 72 experimental bacteremia experiments in mice that are sensitive to human-tropic SAg 73 activity, our findings suggest that the SAgs contribute to persistence of S. aureus 74 bacteremia associated with SSIs.

75 METHODS

76

77 Human ethics statement

78 S. aureus bacteremia patients admitted to the London Health Sciences Centre were 79 identified following a positive bacteremia blood culture test. The S. aureus isolates 80 characterized in study were obtained from Victoria Hospital, London, Ontario, Canada, 81 and delivered to the research laboratory on clinical swabs (Starplex Scientific). Each isolate 82 was assigned a London Health Sciences Centre-S. aureus Bacteremia (SAB) unique number 83 to maintain the patient anonymity. LHSC-SAB numbers were input into an encrypted 84 database to be used to cross-reference patient outcomes at the conclusion of the study. The study was reviewed and approved by the University of Western Ontario Health 85 86 Sciences Research Ethics Board (HSREB #105167). For experiments with human peripheral blood mononuclear cell (PBMC) assays, healthy volunteers were recruited from within the 87 Department of Microbiology and Immunology at the University of Western Ontario, and 88 89 following an outline of the risks, written informed consent was given by each volunteer 90 before each sample was taken. After sampling, blood was anonymized and no information 91 regarding the identity of the donor, including sex and age, was retained as per the study 92 protocol. The study was reviewed and approved by the University of Western Ontario 93 Health Sciences Research Ethics Board (HSREB #110859).

94

95 Bacterial strains and growth conditions

S. aureus strains were routinely grown aerobically at 37°C in tryptic soy broth (TSB) or
brain heart infusion broth (BHI) with shaking (250 rpm) or on tryptic soy agar (TSA)
supplemented with the appropriate antibiotics as needed. For select experiment, *S. aureus* isolates were spotted onto either 5% sheep blood agar or 5% casein (skim milk)
plates and grown overnight to assess hemolytic or proteolytic activity, respectively.
Growth curves were performed using the Biotek Synergy H4 multimode plate reader
(Agilent). *Escherichia coli* XL1-blue was used for cloning purposes and was grown

aerobically at 37°C with shaking (250 rpm) in Luria-Bertani (LB) broth, or on LB agar, with
the appropriate antibiotics.

105

106 Genome sequencing

107 Total DNA preparations from the three *S. aureus* clinical isolates (herein referred to as SAB-0429, SAB-0485, and SAB-0495) were sequenced using paired end Illumina and long 108 109 read nanopore sequencing at SeqCenter, Pittsburgh, USA. Sequence data were used to 110 generate de novo assemblies using SPAdes v3.15 for both chromosome and plasmid DNA 111 and annotated using Prokka v1.12. The genome and plasmid assemblies for the isolates 112 have been deposited at NCBI (Biosamples SAMN42466856, SAMN42466857, 113 SAMN42466858, PQ014898 and PQ014899). A core SNP alignment was built using snippy 114 and snippy-core v4.1 (https://github.com/tseemann/snippy) using these isolates and a 115 small selection of other publicly available CC5 sequences from Canada, and a phylogenetic 116 tree was constructed using FastTree v2.1.10. The presence of previously described SAgs 117 among the genome sequence data set was established by nucleotide BLAST (blastn) as 118 implemented in blastable (https://github.com/bawee/blastable) using a threshold of 90% 119 of identical positions to consider a gene present.

120

121 **T cell activation assays**

122 S. aureus strains were grown in TSB overnight and sub-cultured at 1% into fresh TSB for 123 18 hours, cells were pelleted, and supernatants were filter sterilized. PBMCs were isolated 124 using Ficoll-HyPaque Plus gradients (GE Healthcare), washed three times, and 125 resuspended in complete RPMI (cRPMI) containing RPMI (Invitrogen Life Technologies) 126 supplemented with 10% fetal bovine serum (FBS) (Wisent), 2mM L-glutamine (Gibco), 127 1mM sodium pyruvate (Gibco), 100 µM nonessential amino acids (Gibco), 25mM Hepes 128 (pH 7.2) (Gibco), 100 μ g/mL streptomycin, 100 U/mL penicillin (Gibco) and 2 μ g/mL 129 polymyxin B (Gibco). IL-2 concentrations were determined after 18-hours by ELISA 130 (Invitrogen).

131

132 Proteomic analysis

133 Bacteria were grown in TSB overnight and sub-cultured in fresh TSB for 18 hours, cells 134 were pelleted, and supernatants were harvested and normalized to a OD_{600} = 1.0. 135 Extracellular proteins were precipitated using 6% trichloroacetic acid for 30 minutes on 136 ice. Precipitated proteins were washed in acetone and resuspended in 8M urea. Resulting 137 samples were separated on 12% acrylamide SDS-PAGE gel and analyzed by mass spectrometry. Mass spectrometry analysis was conducted at the London Regional 138 139 Proteomics Centre (University of Western Ontario, London, Canada). Briefly, protein bands 140 within a range of 15-70 kDa were excised using an Ettan Spot Picker (GE Healthcare Life 141 Sciences) and digestion was made in-gel using a Waters MASSPrep Automated Digestor 142 (PerkinElmer Inc). Processed samples were pre-mixed with a matrix-assisted laser 143 desorption ionization (MALDI) matrix and spotted on MALDI target. Sample spots were analyzed using a 5800 MALDI TOF/TOF System (AB Sciex) in reflectron-positive mode, and 144 145 the peptide fingerprint masses were searched against the NCBI database for Grampositive bacteria using the MASCOT search engine. Raw mass spectra of the samples not 146 147 resulting in highly confident identification were processed and compared with the raw 148 data of the samples identified with high confidence using the Data Explorer (AB Sciex).

149

150 **Mice**

151 Human leukocyte antigen (HLA)-DR4-IE (DRB1*0401) transgenic mice lacking endogenous 152 mouse MHC-II on a C57BL/6 background (herein referred to as DR4-B6 mice) [15], or 153 conventional C57BL/6 mice (herein referred to as B6 mice), were used for in vivo infection 154 experiments. Mice were sex-matched for experiments and were between 8- to 12 weeks 155 old. DR4-B6 mice were bred within a barrier facility at the University of Western Ontario 156 and B6 were purchased from Charles River Laboratories. Animals were housed in single-157 sex cages to a maximum of 4 animals per cage. Mice were provided water and food ad 158 libitum and appropriate environmental enrichment was provided. The animal 159 experiments followed the Canadian Council on Animal Care Guide to the Care and Use of

160 Experimental Animals and the protocol was approved by the Animal Care Committee at

the University of Western Ontario (Animal Use Protocol #2020-061).

162

163 Bacteremia infection model

164 Single bacterial colonies were grown in TSB overnight and subcultured at 1% into fresh TSB and grown to post exponential phase (~3 to 4 hours). The bacterial pellets were 165 washed once and resuspended in Hank's balanced salt solution (HBSS---Gibco) to an OD_{600} 166 of 0.15 which corresponds to approximately 5 x 10^7 CFU/mL. Mice were injected via the 167 168 tail vein with $\sim 5 \times 10^6$ CFU of S. *aureus* in a total volume of 100 µL. Mice were weighed 169 and monitored daily. At 3 days post infection, mice were euthanized, and the kidneys and 170 livers were aseptically harvested. Organs were homogenized, plated on mannitol salt agar 171 (MSA), and incubated at 37 °C overnight. S. aureus colonies were enumerated the 172 following day with a limit of detection determined to be 3 CFU per 10 μ L.

173 Interferon- γ (IFN γ) depletion experiments were performed as previously described 174 [13]. Briefly, mice were treated with a 250- μ g dose of anti–IFN- γ (cloneXMG1.2, BioXCell), 175 or a rat IgG1 isotype antibody control (clone HRPN), 18 hours prior to *S. aureus* infection. 176 All antibody doses were prepared in 100 μ L PBS and administered by intraperitoneal 177 injection.

178

179 Curing of the pIB485-like plasmid from *S. aureus* SAB-0485

180 To help understand the direct contribution of the pIB485-like plasmid to S. aureus 181 persistence, we attempted to cure the plasmid by repeatedly growing the strains at 182 elevated temperatures but these experiments did not result in plasmid loss. We therefore 183 took a genetic approach to remove the plasmid where flanking regions of staphylococcal 184 enterotoxin R (ser) gene were PCR amplified, ligated and cloned in pKOR1 integration 185 plasmid within the *attP* sites of the vector as described [16]. The pKOR1::ser plasmid was 186 sequenced to confirm its integrity (Plasmidsaurus) and was subsequently electroporated 187 into competent SAB-0485 as described [17]. Following integration of pKOR1::ser into the 188 pIB485-like plasmid, to select against strains harboring the pIB485-like plasmid containing

the integrated pKOR::*ser* plasmid, bacteria were treated for 3 days with anhydrotetracycline (1 μ g/ml) to induce the anti-sense *secY* counter selection encoded within pKOR1 [16], with subculturing of bacteria in fresh medium with the supplement every day. The final culture was serially diluted and incubated on TSA plates overnight. The colonies were first screened for absence of chloramphenicol resistance from pKOR1 and for absence of ampicillin resistance from pIB485-like. The plasmid-cured antibiotic sensitive strain was confirmed by PCR.

196

197 Statistical analyses

- 198 Statistical analyses were performed using GraphPad Prism 10. A *p* value equal or lower
- than 0.05 was considered to be statistically significant. The bacterial burden calculated in
- 200 the animal experiments were analyzed using the Kruskal-Wallis test with an uncorrected
- 201 Dunn's test for multiple comparisons or Mann-Whitney test.

202 **RESULTS**

203 Patient history

204 A patient in their 70s was admitted to London Health Science Center and received a total 205 right knee arthroplasty, patellaplasty, and bone grafting of the distal femur on the right 206 side to treat osteoarthritis. Following a successful surgery, the site became infected 19-207 days post treatment with a S. aureus positive blood culture (strain SAB-0429), and a 208 second surgery was performed to remove infected tissue. The patient received cefazolin 209 and vancomycin after the second surgery. The patient re-presented at the clinic 107-days 210 post initial surgery with an infection in the right knee, again positive for S. aureus (strain 211 SAB-0485). The patient was treated with vancomycin and sulfamethoxazole and 212 trimethoprim (Septra). An additional sample at the right knee was collected 118 days after 213 the initial surgery that was positive for *S. aureus* (strain SAB-0495). The patient's antibiotic regimen was changed to cefazolin, cloxacillin and vancomycin. After this round of 214 215 treatment, no further cultures of *S. aureus* were recorded.

216

217 Strain analysis indicates the patient was infected with 2 distinct clones of *S. aureus*

218 We next subjected the three SAB isolates to whole genome sequencing and created de 219 novo assemblies of each of the isolates to determine genetic relationships. In silico multi-220 locus sequence type (MLST) analysis indicated that all three isolates were sequence type 221 (ST) 5 (Table S1) belonging to clonal complex (CC) 5. Using a selection of publicly available 222 CC5 sequences from Canada, we determined that despite being of the same clonal 223 lineage, these isolates were not closely related, and the SAB-0429 isolate was in a distinct 224 clade from the SAB-0485 and SAB-0495 isolates (Figure 1A). Further using the 225 Comprehensive Antibiotic Resistance Database (CARD) [18], we were able to confirm that 226 SAB-0429 was an MRSA encoding the Staphylococcal Cassette Chromosome mec 227 (SCCmec) element (Table S2). Curiously, the CARD analysis also identified that the SAB-228 0485 and SAB-0495 isolates encode the BlaZ beta lactamase, but this was not present in 229 the SAB-0429 isolate (Table S2). These data indicate that the patient was infected first 230 with a clone of CC5 MRSA that was supplanted by a different CC5 MSSA.

231 SAB-0485 and SAB-0495 have a unique set of SAgs encoded on pIB485-like plasmid

232 To evaluate if these strains had any difference in pathogenic potential, we assessed the 233 genome sequencing data to determine the virulence factor composition present in these 234 isolates. In specific reference to SAg genes, all three isolates were found to encode the 235 staphylococcal enterotoxin genes seq, sei, selM, selN, selW and selX; however the sed, sej 236 and ser genes were only in isolates SAB-0485 and SAB-0495. These three SAgs have usually 237 been found encoded together within pIB485-like plasmids [19,20] and the presence of 238 this plasmid in the two MSSA isolates was confirmed by assembling the plasmid from the 239 combined long and short sequencing using *de novo* assembly (Figure 1B).

240 To evaluate if one or all three SAgs were being expressed by SAB-0485 and SAB-241 0495, the extracellular proteins produced in bacterial culture from the three bacterial strains were subjected to proteomic analysis. First, SDS-PAGE analysis confirmed that the 242 243 secreted profiles between the MSSA and MRSA isolates were quite different. This was 244 further confirmed by mass spectrometry analysis (**Table S3**). SAB-0429 produced several 245 toxins including the pro and mature forms of glycerol-ester hydrolase (Geh), nuclease 246 (Nuc), leukocidins (LukED) and gamma hemolysins (HlgAB) (Figure 1C); however, no SAg 247 peptides were detected from S. aureus SAB-0429. However, from SAB-0485 and SAB-0495 248 supernatants, the SAg SER was identified (solid arrow, Figure 1C). Notably, we also 249 detected α -hemolysin (Hla) by mass spectrometry from both SAB-0485 and SAB-0495, but 250 not SAB-0429 (Table S3).

251

252 SAB-0485 and SAB-0495 produce increased levels of superantigen activity

To better understand how *S. aureus* may have persisted during infection, the three isolates were subjected to a range of phenotypic tests. First, the growth profile of all three isolates were assessed in rich bacterial media (tryptone soy broth) and the strains grew similar (**Figure 2A**). To evaluate if differences in cytolytic toxin expression had an impact, hemolytic profiles of three isolates were determined by spotted the strains on TSA agar containing 5% sheep blood. Hemolysis was observed for all three isolates although this activity was decreased from the SAB-0429 isolate compared to the SAB-0485 and SAB-

260 0495 isolates (Figure 2B), consistent with an apparent reduced capacity to produce Hla 261 (Table S3). In parallel, the isolates were spotted on 5% casein hydrolysis plates (skim milk 262 plates) to examine protease activity although no differences in proteolytic activity were 263 observed (Figure 2B). Next, to evaluate if the presence of the additional plasmid encoded 264 SAgs correlated with an increased ability to induce higher levels of T cell activation, we 265 incubated primary human PBMCs with filter sterilized supernatant from each isolate and 266 measured the production of IL-2. Compared to SAB-0429, both SAB-0485 and SAB-0495 267 were able to consistently induce T cell activation at lower supernatant dilutions, indicating 268 that the presence of the pIB485-like plasmid correlated with higher superantigenic 269 capacity in the two MSSA isolates (Figure 2C). Taken together, the genetic and phenotypic 270 analyses suggest that antibiotic treatment for the initial MRSA infection with SAB-0429 271 was successful, although the patient became reinfected with a persistent MSSA isolate 272 that produced larger amounts of virulence promoting toxins.

273

274 Isolates containing the pIB485-like plasmid persist at higher level in the liver

275 The increased superantigen activity of the MSSA isolates (Figure 2C) may have promoted 276 persistence of these strains following the second surgery and the relapse of infection in 277 the patient's knee. To evaluate if the SAB-0485 and SAB-0495 strains exhibited increased 278 persistence in vivo compared to the SAB-0429 isolate, we utilized an experimental model 279 of bacteremia in transgenic mice that express human MHC-II molecules (DR4-B6) and are 280 sensitive to SAg function [13,21]. The susceptibility of the DR4-B6 strain to exoproteins 281 secreted by each S. aureus strain was tested by exposing extracted splenocytes with 282 isolate supernatants and assessing for IL-2 production. Supernatants from both SAB-0485 283 and SAB-0495 resulted in an increased production of IL-2 compared to SAB-0429, 284 especially visible at the dilution factor of $\sim 1/250$, noting that the more concentrated 285 supernatants contain active cytolytic toxins that kill the immune cells (Figure 3A). To 286 identify pathogenic differences between these strains during experimental bacteremia, 287 DR4-B6 mice were intravenously inoculated with the different S. aureus isolates and 288 bacterial burden in the liver and kidneys were assessed 3 days post-inoculation. The

bacterial burden in the liver of DR4-B6 mice was increased for both SAB-0485 and SAB-0495 compared with SAB-0429 (**Figure 3B**), although there were no differences in bacterial counts in the kidneys (**Figure 3C**). These data suggest that the SAgs encoded on the pIB485-like plasmid may be involved in promoting the persistence of the latter SAB-0485 and SAB-0495 isolates compared with the initial SAB-0429 isolate during bloodstream infection.

295 Hla has also been implicated in liver persistence by *S. aureus* [15]. As this toxin 296 showed increased expression from the proteomic analysis (**Table S3**) and that phenotypic 297 assessment showed decreased hemolytic activity for SAB-0429 (Figure 2B), it was 298 important to evaluate a potential role of Hla in the bacteremia model. Conventional 299 mouse models are sensitive to the activity of this toxin [22]; therefore, we repeated our 300 bacteremia analysis in conventional B6 mice. Splenocytes from conventional B6 mice were 301 first co-incubated with supernatants from each isolate which did not induce any 302 detectable T cell activation, confirming the lack of susceptibility of these mice to SAg 303 (Figure 3D). Next, the experimental bacteremia experiment was repeated in conventional 304 B6 mice and although there was a trend suggesting increased bacterial recovery from the 305 liver for the two MSSA isolates, this was not statistically different (Figure 3E). As with the 306 DR4-B6 mouse experiments, there were no obvious differences in bacterial counts 307 recovered from the kidneys. These collective data suggest that the differences we 308 observed between the tested S. aureus strains was due primarily to the additional SAgs 309 encoded by SAB-0485 and SAB-0495, rather than the expression of other virulence factors.

310

311 Loss of pIB485-like decreases the bacterial burden in the liver

To determine if the increased bacterial burden within the liver of DR4-B6 mice was due to the set of SAgs encoded within pIB485-like plasmid, the cured this plasmid from SAB-0485 and this strain was evaluated using the bacteremia model in DR4-B6 mice. First, the supernatants from either wildtype *S. aureus* SAB-0485 or the isogenic strain lacking the pIB485-like plasmid were tested for IL-2 production from DR4-B6 splenocytes and a decreased stimulation of PBMC was observed with the plasmid cured strain (**Figure 4A**).

We hypothesized that this decrease in T cell stimulation would correlate with decreased bacterial burden within the liver in the DR4-B6 bloodstream infection model. Indeed, in absence of the pIB485-like plasmid, this strain reached a lower bacterial burden in the liver of the mice compared to wild-type SAB-0429 (**Figure 4B**).

322

323 pIB485-like encoded SAgs promote a pathogenic IFNγ response

324 We previously demonstrated that SAgs could promote a pathogenic IFNy response that 325 modifies macrophage responses and allows S. aureus to persist and replicate more 326 effectively within macrophages [13]. This mechanism could potentially explain why the 327 two MSSA isolates persisted for longer in the patient compared with the MRSA clone 328 despite antibiotic treatment. To test this hypothesis, we utilized an IFNy depletion 329 protocol in DR4-B6 mice prior to infection with either SAB-0429 or SAB-0485, and bacterial 330 liver and kidney burdens were enumerated at 72 hours post-infection (Figure 5A). For 331 infections with S. aureus SAB-0429, depletion of IFNy had no measurable impact on 332 bacterial recovery from the liver or kidneys compared to the isotype antibody treatment 333 control. For animals infected with S. aureus SAB-0485, IFNy depletion resulted in a 334 significant reduction in bacterial recovery from the liver (**Figure 5***B*) but again did not alter 335 kidney burden (Figure 5C). Importantly, the IFNy depletion for the SAB-0485 isolate 336 reduced bacterial recovery in the liver that was equivalent to the SAB-0429 isolate, 337 indicating that removing the pathogenic IFNy production mitigated the activity of the 338 plasmid encoded SAgs. Together this demonstrates that the pIB485-like encoded SAgs can 339 promote excessive IFNy production and promote bacterial persistence of these isolates 340 during experimental bacteremia.

341 Discussion

342 S. aureus infections acquired in the hospital setting can result in life-threatening 343 disease and poor outcomes which may be further complicated by antimicrobial resistance. 344 In addition, microbial mechanisms that promote persistence during infection can further 345 exacerbate disease. In this work, we encountered MSSA isolates of S. aureus that were 346 able to persist in a patient despite antimicrobial therapy. Based on comparisons with the earlier MRSA isolate from the same patient, and combined with experimental infection 347 348 models, we were able to determine that the increased persistence of these MSSA strains 349 was associated with the production of plasmid-encoded SAg toxins. We initially 350 considered that this may be an example of in-patient evolution, but genome sequencing 351 determined that although the main differentiating determinant of the strains was the 352 pIB485-like plasmid, the SAB-0429 isolate was not ancestral to the SAB-0485 and SAB-353 0495 isolates (Figure 1A). Therefore, this patient may have been colonized simultaneously 354 at the injury site with different S. aureus clones or was subsequently infected during the 355 period between presentations at the clinic.

356 All three *S. aureus* isolates were identified to be members of the CC5 clade. This 357 clonal complex is a clinically important group and frequently isolated from nosocomial 358 infections. In Ontario and Canada, CC5 has been related with community-associated 359 infections, especially in the case of MRSA isolates [23]. Strains from CC5 also harbor high 360 variability in their SAg complement, and this can include the presence or absence of the pIB485 -like plasmid in both MRSA and MSSA lineages of this clonal complex [23]. Indeed, 361 362 the pIB485-like plasmid contributed to this genetic variability between the MRSA isolates 363 in this study. Interestingly, multiple experiments growing S. aureus SAB-0485 at elevated 364 temperatures did not result in curing of this plasmid, suggesting this is a stable genetic 365 element in S. aureus that may be associated with persistent infection and worse patient 366 outcome.

The MSSA isolates we identified were able to survive in the patient in between disease episodes and cause resurgence of bacteremia despite high levels of antibiotic stress. Subsequently, we were able to demonstrate that the MSSA isolates were persisting

370 in experimental *in vivo* bacteremia model, in part, by inducing a pathogenic IFNy response 371 (Figure 5). We previously demonstrated that this mechanism could support the replication 372 of S. aureus inside macrophages and allow the bacteria to persist in vivo. Further, being 373 able to persist and replicate within a macrophage may effectively contribute to avoidance 374 of killing by antibiotics [13]. Other mechanisms of persistence within macrophages have 375 been previously described for many bacterial pathogens; however these mechanisms 376 usually include a 'persister-type' phenotype [24,25]. In the current study, S. aureus 377 persistence may allow survival of the bacterium independent of this persister phenotype 378 as the quick recovery of bacteria following the organs collection suggests that S. aureus 379 was in a replicative state in the animal. Although both SAB-0485 and SAB-0495 harbored 380 several SAg genes, only SER was detected from *in vitro* conditions by proteomics, and we 381 demonstrated that this impacted the bacterial burden within the liver during bacteremia. 382 Altogether, SER demonstrated similar characteristics to SEA [21], SEB and SEC [13], and 383 SEI-W [26] produced from other S. aureus strains in bloodstream infections by enhancing 384 persistence in the liver.

385 Due to limitations in sampling, we were unable to fully establish how this patient 386 experienced infections with two distinct clones of S. aureus. Samples at admission were 387 not retained so we were unable to assess if this patient was nasally colonized prior to 388 infection, and if this was the source of the surgical complication. During the disease, both 389 co-infection with the MSSA and MRSA clones is possible as well as hematological spread 390 from another source. In both scenarios, a virulence mechanism that enhanced survival in 391 macrophages would have provided a selective advantage for the MSSA strains in the 392 patient and may have led to the clearance of the MRSA clone.

This study highlights how virulence factors may provide an evolutionary advantage to *S. aureus* strains in certain patient settings. Beyond classical antimicrobial resistance mechanisms, *S. aureus* is also potent at manipulating its environment and shielding itself from the immune system. Although these findings do not diminish the concerns around antimicrobial resistance, this research demonstrates the importance of considering the

- 398 niche of *S. aureus,* the range of virulence factors encoded in its genome, and factors that
- are produced by the bacterium during infection that contribute to disease.
- 400
- 401 **Financial support.** This work was supported by an operating grant from the Canadian
- 402 Institutes of Health Research (CIHR) (PJT-166050) to S.W.T, T. S. M. and J.K.M and D.E.H
- 403 acknowledges funding from CIHR grant PJT-168842.

404 References

- Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of Mortality in *Staphylococcus aureus* Bacteremia. Clin Microbiol Rev. **2012**;
 25(2):362–386.
- Lam JC, Stokes W. The Golden Grapes of Wrath *Staphylococcus aureus* Bacteremia: A Clinical Review. The American Journal of Medicine. **2023**; 136(1):19–
 26.
- Vestergaard M, Frees D, Ingmer H. Antibiotic Resistance and the MRSA Problem.
 Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Braunstein M, Rood JI, editors.
 Microbiol Spectr. 2019; 7(2):7.2.18.
- Anderson DJ, Kaye KS, Chen LF, et al. Clinical and Financial Outcomes Due to
 Methicillin Resistant *Staphylococcus aureus* Surgical Site Infection: A Multi-Center
 Matched Outcomes Study. PLoS ONE. **2009**; 4(12):e8305.
- Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The Impact of
 Surgical-Site Infections Following Orthopedic Surgery at a Community Hospital and
 a University Hospital Adverse Quality of Life, Excess Length of Stay, and Extra Cost.
 Infect Control Hosp Epidemiol. 2002; 23(4):183–189.
- 421 6. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-Resistant Pathogens Associated
 422 With Healthcare-Associated Infections: Annual Summary of Data Reported to the
 423 National Healthcare Safety Network at the Centers for Disease Control and
 424 Drevention 2006 2007 Infect Centrol Lloca Enidemial 2008 20(11):006 1011
- 424 Prevention, 2006–2007. Infect Control Hosp Epidemiol. **2008**; 29(11):996–1011.
- Portigliatti Barbos M, Mognetti B, Pecoraro S, Picco W, Veglio V. Decolonization of
 orthopedic surgical team *S. aureus* carriers: impact on surgical-site infections. J
 Orthopaed Traumatol. **2010**; 11(1):47–49.
- 428 8. Wilcox MH, Hall J, Pike H, et al. Use of perioperative mupirocin to prevent
 429 methicillin-resistant *Staphylococcus aureus* (MRSA) orthopaedic surgical site
 430 infections. Journal of Hospital Infection. **2003**; 54(3):196–201.
- Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing Surgical-Site Infections
 in Nasal Carriers of *Staphylococcus aureus*. N Engl J Med. **2010**; 362(1):9–17.
- Horváth A, Dobay O, Sahin-Tóth J, et al. Characterisation of antibiotic resistance,
 virulence, clonality and mortality in MRSA and MSSA bloodstream infections at a
 tertiary-level hospital in Hungary: a 6-year retrospective study. Ann Clin Microbiol
 Antimicrob. 2020; 19(1):17.

- Tuffs SW, Dufresne K, Rishi A, Walton NR, McCormick JK. Novel insights into the
 immune response to bacterial T cell superantigens. Nat Rev Immunol. 2024;
 24:417–434.
- 440 12. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial
 441 superantigens: An update. Annu Rev Microbiol. 2001; 55(1):77–104.
- Tuffs SW, Goncheva MI, Xu SX, et al. Superantigens promote *Staphylococcus aureus*bloodstream infection by eliciting pathogenic interferon-gamma production. Proc
 Natl Acad Sci USA. Proceedings of the National Academy of Sciences; **2022**;
 119(8):e2115987119.
- 446 14. Xu S, Kasper K, Zeppa J, McCormick J. Superantigens modulate bacterial density
 447 during *Staphylococcus aureus* nasal colonization. Toxins. **2015**; 7(5):1821–1836.
- 448 15. Surewaard BGJ, Thanabalasuriar A, Zeng Z, et al. α-Toxin induces platelet
 449 aggregation and liver injury during *Staphylococcus aureus* sepsis. Cell host &
 450 microbe. NIH Public Access; **2018**; 24(2):271-284.e3.
- 451 16. Bae T, Schneewind O. Allelic replacement in *Staphylococcus aureus* with inducible
 452 counter-selection. Plasmid. **2006**; 55(1):58–63.
- 453 17. Monk IR, Shah IM, Xu M, Tan M-W, Foster TJ. Transforming the untransformable:
 454 Application of direct transformation to manipulate genetically *Staphylococcus*455 *aureus* and *Staphylococcus epidermidis*. Novick RP, editor. mBio. American Society
 456 for Microbiology; **2012**; 3(2).
- Alcock BP, Huynh W, Chalil R, et al. CARD 2023: expanded curation, support for
 machine learning, and resistome prediction at the Comprehensive Antibiotic
 Resistance Database. Nucleic Acids Res. 2023; 51(D1):D690–D699.
- 460 19. Bayles KW, landolo JJ. Genetic and molecular analyses of the gene encoding
 461 staphylococcal enterotoxin D. J Bacteriol. **1989**; 171(9):4799–4806.
- 462 20. Omoe K, Hu D-L, Takahashi-Omoe H, Nakane A, Shinagawa K. Identification and
 463 characterization of a new staphylococcal enterotoxin-related putative toxin
 464 encoded by two kinds of plasmids. Infect Immun. 2003; 71(10):6088–6094.
- 465 21. Xu SX, Gilmore KJ, Szabo PA, et al. Superantigens subvert the neutrophil response
 466 to promote abscess formation and enhance *Staphylococcus aureus* survival in vivo.
 467 Infect Immun. **2014**; 82(9):3588–98.
- 468 22. Bubeck Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores:
 469 α-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia.
 470 Nat Med. **2007**; 13(12):1405–1406.

471 23. Guthrie JL, Teatero S, Hirai S, et al. Genomic Epidemiology of Invasive Methicillin-472 Resistant Staphylococcus aureus Infections Among Hospitalized Individuals in 473 Ontario, Canada. The Journal of Infectious Diseases. 2020; 222(12):2071–2081. 474 24. Dadole I, Blaha D, Personnic N. The macrophage–bacterium mismatch in persister 475 formation. Trends in Microbiology. 2024; :S0966842X24000490. 476 25. Fauerharmel-Nunes T, Flannagan RS, Goncheva MI, et al. MRSA Isolates from 477 Patients with Persistent Bacteremia Generate Nonstable Small Colony Variants In 478 Vitro within Macrophages and Endothelial Cells during Prolonged Vancomycin 479 Exposure. Torres VJ, editor. Infect Immun. 2023; 91(1):e00423-22. 480 26. Vrieling M, Tuffs SW, Yebra G, et al. Population analysis of Staphylococcus aureus 481 reveals a cryptic, highly prevalent superantigen SEIW that contributes to the 482 pathogenesis of bacteremia. Projan SJ, editor. mBio. 2020; 11(5):e02082-20.

484 Figure legends

485

486 Figure 1. The initial methicillin-resistant S. aureus SAB-0429 isolate is genetically distinct 487 from methicillin-sensitive S. aureus SAB-0485 and SAB-0495 isolates. (A) Phylogenetic 488 tree of S. aureus CC5 strains including isolates SAB-0429, SAB-0485 and SAB-0495. Core 489 SNPs (single nucleotide polymorphisms) were identified using Snippy in the three patient 490 isolates and a small selection of other publicly available CC5 sequences from Canada. A 491 maximum likelihood phylogeny was constructed from the aligned SNPs using FastTree 492 v2,1,10. (B) The sequence of the pIB485-like plasmid found in both *S. aureus* SAB-0485 493 and SAB-0495 is presented with its main characteristics (e.g. *bla* genes and superantigen-494 encoding genes). (C) Exoprotein profiles from S. aureus SAB-0429, SAB-0485 and SAB-0495 495 visualized on SDS-PAGE. Open arrows indicated virulence factors found in all three isolates 496 and the solid arrow indicates SER that was only found in SAB-0485 and SAB-0495.

497

498 Figure 2. Phenotypic analyses demonstrate enhance superantigen activity from S. 499 aureus SAB-0485 and SAB-0495 compared to SAB-0429.

500 (A) The three S. aureus patient isolates were grown in TSB for 24 hours with agitations in 501 a multimode plate reader and their optical density at 600 nm was monitored every hour. 502 Each data point represents the mean of three independent experiments. (B). Hemolytic 503 and proteolytic activity of each isolate assessed on 5% sheep blood TSA plates and skim 504 milk agar plate, respectively. The image is a representative image of experiments 505 replicated at least three times. (C) IL-2 production from supernatants from each isolate 506 grown in TSB for 18 hours. Supernatants were filter-sterilized before exposure to human 507 PBMCs and IL-2 concentrations were measured by ELISA. Each data point represents the 508 mean ± SEM of three independent experiments using different donors.

509

510 Figure 3. *S. aureus* isolates SAB-0485 and SAB-0495 containing the pAB485-like plasmid 511 persist at a higher bacterial counts compared to SAB-0429 in a SAg-sensitive model of

512 bacteremia. DR4-B6 (A) or B6 (D) splenocytes were isolated and challenged against

513 supernatant issued from each bacterial isolate and IL-2 production from stimulated cells 514 was measure by ELISA. Data presented is the mean of three independent experiments 515 \pm SD. Each isolate was intravenously injected at 5 x 10⁷ CFU/mL to DR4-B6 (B&C) or B6 516 (E&F) animals and bacterial burden of both kidneys (B&E) and liver (C&F) was assessed 3 517 days post-infection. Each dot represents one animal. The results are represented as the 518 geometric mean of at least 8 biological replicates \pm geometric SD. Significant differences 519 were determined using the Kruskal-Wallis test with the uncorrected Dunn's test for 520 multiple comparisons (*P < 0.05).

521

522 Figure 4. Loss of the pIB485-like plasmid in the SAB-0485 isolate demonstrates a 523 decreased bacterial burden in the liver. (A) B6-DR4 splenocytes were isolated and 524 challenged against supernatant issued from each bacterial strain (SAB-0485 or SAB-0485 525 without plasmid). The graph represents murine IL-2 quantification during at least three 526 independent experiments. (B) The same strains were intravenously injected to DR4-B6 527 animals to perform the bacteremia model and the bacterial burden in the liver is 528 represented as the geometric mean of at least 7 animals \pm geometric SD. Each dot 529 represents one mouse. Significant differences were determined using Mann Whitney test 530 (*P < 0.05).

531

532 Figure 5. Depletion of Interferon gamma eliminates SER-mediated bacterial persistence 533 during S. aureus bacteremia. (A) The bacteremia model was repeated with the isolates 534 SAB-0429 and SAB-0485 after intraperitoneally injecting the animal with either depleting 535 antibodies for IFN γ or an isotype control 18 hours before *S. aureus* intravenous challenge. Both the kidneys (B) and the liver (C) were collected and homogenized for bacterial 536 537 burden. The results are represented as the geometric mean of at least 8 biological 538 replicates \pm geometric SD. Significant differences were determined using the Kruskal-539 Wallis test with the uncorrected Dunn's test for multiple comparisons (*P < 0.05).



Figure 1.



Figure 2.



Figure 3.



Figure 4.



Figure 5.